Open access
Open access
Powered by Google Translator Translator

#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.

30 Aug, 2022 | 12:12h | UTC

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT – Circulation

News Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology

Related:

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials – Journal of Thrombosis and Thrombolysis

Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis – Open Forum Infectious Diseases

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.